Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development

Copyright: zneb076 / 123RF Stock Photo

For starters, it is preparing for the end-of-phase 2 gathering with the US Food and Drug Administration for pilavapadin, a campaigner cause targeting neuropathic pain. Additionally, it is accelerating diligent enrollment successful the SONATA proceedings for hypertrophic cardiomyopathy (HCM). Lexicon is besides resubmitting Zynquista for benignant 1 diabetes to the FDA successful aboriginal 2026.

On November 10, astatine the American Heart Association Annual Scientific Sessions 2025, Lexicon delivered topline results for sotagliflozin, showing important improvements successful bosom nonaccomplishment patients with preserved ejection fraction.

“Although sotagliflozin was approved much than 2 years agone for bosom nonaccomplishment patients with oregon without diabetes, our survey is the archetypal to show important objective benefits for patients with preserved ejection fraction without diabetes,” said Dr. Juan J Badimon astatine Mount Sinai Medical Center.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is simply a biopharmaceutical institution that discovers, develops, and commercializes medicines for superior and chronic diseases. The institution focuses connected cardiometabolic (heart and metabolic health) and neuroscience (nervous system) conditions.

While we admit the imaginable of LXRX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: Top 10 Stocks Offering High Upside Potential successful Data Centers and 10 Best Breakout Stocks to Invest In.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.